Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data.

Cole MJ, Quaye N, Jacobsson S, Day M, Fagan E, Ison C, Pitt R, Seaton S, Woodford N, Stary A, Pleininger S, Crucitti T, Hunjak B, Maikanti P, Hoffmann S, Viktorova J, Buder S, Kohl P, Tzelepi E, Siatravani E, Balla E, Hauksdóttir GS, Rose L, Stefanelli P, Carannante A, Pakarna G, Mifsud F, Cassar RZ, Linde I, Bergheim T, Steinbakk M, Mlynarczyk-Bonikowska B, Borrego MJ, Shepherd J, Pavlik P, Jeverica S, Vazquez J, Abad R, Weiss S, Spiteri G, Unemo M.

BMC Infect Dis. 2019 Mar 25;19(1):281. doi: 10.1186/s12879-019-3900-z.

2.

attI1-Located Small Open Reading Frames ORF-17 and ORF-11 in a Class 1 Integron Affect Expression of a Gene Cassette Possessing a Canonical Shine-Dalgarno Sequence.

Papagiannitsis CC, Tzouvelekis LS, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02070-16. doi: 10.1128/AAC.02070-16. Print 2017 Mar.

3.

WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014.

Jacobsson S, Golparian D, Cole M, Spiteri G, Martin I, Bergheim T, Borrego MJ, Crowley B, Crucitti T, Van Dam AP, Hoffmann S, Jeverica S, Kohl P, Mlynarczyk-Bonikowska B, Pakarna G, Stary A, Stefanelli P, Pavlik P, Tzelepi E, Abad R, Harris SR, Unemo M.

J Antimicrob Chemother. 2016 Nov;71(11):3109-3116. Epub 2016 Jul 17.

PMID:
27432597
4.

Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.

Kotsakis SD, Miriagou V, Vetouli EE, Bozavoutoglou E, Lebessi E, Tzelepi E, Tzouvelekis LS.

Antimicrob Agents Chemother. 2015 Dec;59(12):7894-8. doi: 10.1128/AAC.01793-15. Epub 2015 Oct 5.

5.

Characterization of a mobilizable IncQ plasmid encoding cephalosporinase CMY-4 in Escherichia coli.

Kotsakis SD, Tzouvelekis LS, Lebessi E, Doudoulakakis A, Bouli T, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2015 May;59(5):2964-6. doi: 10.1128/AAC.05017-14. Epub 2015 Feb 17. No abstract available.

6.

Emergence and maintenance of multidrug-resistant Escherichia coli of canine origin harbouring a blaCMY-2-IncI1/ST65 plasmid and topoisomerase mutations.

Vingopoulou EI, Siarkou VI, Batzias G, Kaltsogianni F, Sianou E, Tzavaras I, Koutinas A, Saridomichelakis MN, Sofianou D, Tzelepi E, Miriagou V.

J Antimicrob Chemother. 2014 Aug;69(8):2076-80. doi: 10.1093/jac/dku090. Epub 2014 Apr 9.

PMID:
24722836
7.

OmpK35 and OmpK36 porin variants associated with specific sequence types of Klebsiella pneumoniae.

Papagiannitsis CC, Giakkoupi P, Kotsakis SD, Tzelepi E, Tzouvelekis LS, Vatopoulos AC, Miriagou V.

J Chemother. 2013 Aug;25(4):250-4. doi: 10.1179/1973947813Y.0000000075. No abstract available.

PMID:
23906079
8.

KPC-producing, multidrug-resistant Klebsiella pneumoniae sequence type 258 as a typical opportunistic pathogen.

Tzouvelekis LS, Miriagou V, Kotsakis SD, Spyridopoulou K, Athanasiou E, Karagouni E, Tzelepi E, Daikos GL.

Antimicrob Agents Chemother. 2013 Oct;57(10):5144-6. doi: 10.1128/AAC.01052-13. Epub 2013 Jul 15.

9.

Laboratory evaluation of Brilliance™ CRE Agar for screening carbapenem-resistant Enterobacteriaceae: Performance on a collection of characterised clinical isolates from Greece.

Kotsakis SD, Petinaki E, Scopes E, Siatravani E, Miriagou V, Tzelepi E.

J Glob Antimicrob Resist. 2013 Jun;1(2):85-90. doi: 10.1016/j.jgar.2013.03.004. Epub 2013 Apr 16.

PMID:
27873583
10.

Combined disc methods for the detection of KPC- and/or VIM-positive Klebsiella pneumoniae: improving reliability for the double carbapenemase producers.

Miriagou V, Tzelepi E, Kotsakis SD, Daikos GL, Bou Casals J, Tzouvelekis LS.

Clin Microbiol Infect. 2013 Sep;19(9):E412-5. doi: 10.1111/1469-0691.12238. Epub 2013 Apr 30.

11.

Characterization of a transmissible plasmid encoding VEB-1 and VIM-1 in Proteus mirabilis.

Papagiannitsis CC, Miriagou V, Kotsakis SD, Tzelepi E, Vatopoulos AC, Petinaki E, Tzouvelekis LS.

Antimicrob Agents Chemother. 2012 Jul;56(7):4024-5. doi: 10.1128/AAC.00470-12. Epub 2012 Apr 30. No abstract available.

12.

Diversity of acquired β-lactamases amongst Klebsiella pneumoniae in Greek hospitals.

Papagiannitsis CC, Tryfinopoulou K, Giakkoupi P, Pappa O, Polemis M, Tzelepi E, Tzouvelekis LS; Carbapenemase Study Group, Vatopoulos AC.

Int J Antimicrob Agents. 2012 Feb;39(2):178-80. doi: 10.1016/j.ijantimicag.2011.09.024. Epub 2011 Nov 21. No abstract available.

PMID:
22104281
13.

Effects of the Val211Gly substitution on molecular dynamics of the CMY-2 cephalosporinase: implications on hydrolysis of expanded-spectrum cephalosporins.

Kotsakis SD, Tzouvelekis LS, Petinaki E, Tzelepi E, Miriagou V.

Proteins. 2011 Nov;79(11):3180-92. doi: 10.1002/prot.23150. Epub 2011 Aug 30.

PMID:
21989938
14.

Characterization of metallo-beta-lactamase VIM-27, an A57S mutant of VIM-1 associated with Klebsiella pneumoniae ST147.

Papagiannitsis CC, Kotsakis SD, Petinaki E, Vatopoulos AC, Tzelepi E, Miriagou V, Tzouvelekis LS.

Antimicrob Agents Chemother. 2011 Jul;55(7):3570-2. doi: 10.1128/AAC.00238-11. Epub 2011 Apr 25.

15.

Analysis of emergence of quinolone-resistant gonococci in Greece by combined use of Neisseria gonorrhoeae multiantigen sequence typing and multilocus sequence typing.

Mavroidi A, Tzelepi E, Siatravani E, Godoy D, Miriagou V, Spratt BG.

J Clin Microbiol. 2011 Apr;49(4):1196-201. doi: 10.1128/JCM.02233-10. Epub 2011 Jan 19.

16.

Sequence of pR3521, an IncB plasmid from Escherichia coli encoding ACC-4, SCO-1, and TEM-1 beta-lactamases.

Papagiannitsis CC, Tzouvelekis LS, Kotsakis SD, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2011 Jan;55(1):376-81. doi: 10.1128/AAC.00875-10. Epub 2010 Oct 18.

17.

Detection of metallo-β-lactamase genes in clinical specimens by a commercial multiplex PCR system.

Avlami A, Bekris S, Ganteris G, Kraniotaki E, Malamou-Lada E, Orfanidou M, Paniara O, Pantazatou A, Papagiannitsis CC, Platsouka E, Stefanou I, Tzelepi E, Vagiakou H, Miriagou V.

J Microbiol Methods. 2010 Nov;83(2):185-7. doi: 10.1016/j.mimet.2010.08.014. Epub 2010 Aug 31.

PMID:
20807554
18.

Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.

Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.

Antimicrob Agents Chemother. 2010 Nov;54(11):4864-71. doi: 10.1128/AAC.00771-10. Epub 2010 Aug 9.

19.

Sequence of pNL194, a 79.3-kilobase IncN plasmid carrying the blaVIM-1 metallo-beta-lactamase gene in Klebsiella pneumoniae.

Miriagou V, Papagiannitsis CC, Kotsakis SD, Loli A, Tzelepi E, Legakis NJ, Tzouvelekis LS.

Antimicrob Agents Chemother. 2010 Oct;54(10):4497-502. doi: 10.1128/AAC.00665-10. Epub 2010 Jul 26.

20.

The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2.

Zioga A, Miriagou V, Tzelepi E, Douzinas E, Tsakiri M, Legakis NJ, Daikos GL, Tzouvelekis LS.

Int J Antimicrob Agents. 2010 Aug;36(2):190-1. doi: 10.1016/j.ijantimicag.2010.04.002. Epub 2010 May 26. No abstract available.

PMID:
20510588
21.

GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.

Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS.

Antimicrob Agents Chemother. 2010 Mar;54(3):1331-3. doi: 10.1128/AAC.01561-09. Epub 2010 Jan 11.

22.

Detecting VIM-1 production in Proteus mirabilis by an imipenem-dipicolinic acid double disk synergy test.

Miriagou V, Papagiannitsis CC, Tzelepi E, Casals JB, Legakis NJ, Tzouvelekis LS.

J Clin Microbiol. 2010 Feb;48(2):667-8. doi: 10.1128/JCM.01872-09. Epub 2009 Dec 9. No abstract available.

23.

Changing figures of antimicrobial susceptibility and serovar distribution in Neisseria gonorrhoeae isolated in Greece.

Tzelepi E, Avgerinou H, Flemetakis A, Siatravani E, Stathi M, Daniilidou M, Miriagou V.

Sex Transm Dis. 2010 Feb;37(2):115-20. doi: 10.1097/OLQ.0b013e3181bcd0b8.

PMID:
19901866
24.

Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.

Kotsakis SD, Papagiannitsis CC, Tzelepi E, Tzouvelekis LS, Miriagou V.

Antimicrob Agents Chemother. 2009 Aug;53(8):3520-3. doi: 10.1128/AAC.00219-09. Epub 2009 May 26.

25.

CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.

Zioga A, Whichard JM, Kotsakis SD, Tzouvelekis LS, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2009 Mar;53(3):1256-9. doi: 10.1128/AAC.01284-08. Epub 2008 Dec 22.

26.

Cluster of multidrug-resistant Neisseria gonorrhoeae with reduced susceptibility to the newer cephalosporins in Northern Greece.

Tzelepi E, Daniilidou M, Miriagou V, Siatravani E, Pavlidou E, Flemetakis A.

J Antimicrob Chemother. 2008 Sep;62(3):637-9. doi: 10.1093/jac/dkn236. Epub 2008 Jun 12. No abstract available.

PMID:
18556708
27.

Evidence for chromosomal and plasmid location of CMY-2 cephalosporinase gene in Salmonella serotype Typhimurium.

Zioga A, Whichard JM, Joyce KJ, Tzelepi E, Tzouvelekis LS, Miriagou V.

J Antimicrob Chemother. 2008 Jun;61(6):1389-90. doi: 10.1093/jac/dkn116. Epub 2008 Mar 18. No abstract available.

PMID:
18349038
28.

Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.

Loli A, Tzouvelekis LS, Gianneli D, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2008 May;52(5):1894-6. doi: 10.1128/AAC.01414-07. Epub 2008 Feb 19. No abstract available.

29.

Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.

Papagiannitsis CC, Tzouvelekis LS, Tzelepi E, Miriagou V.

Antimicrob Agents Chemother. 2007 Oct;51(10):3763-7. Epub 2007 Jul 30.

30.

SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.

Papagiannitsis CC, Loli A, Tzouvelekis LS, Tzelepi E, Arlet G, Miriagou V.

Antimicrob Agents Chemother. 2007 Jun;51(6):2185-8. Epub 2007 Mar 12.

31.

Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model.

Daikos GL, Panagiotakopoulou A, Tzelepi E, Loli A, Tzouvelekis LS, Miriagou V.

Clin Microbiol Infect. 2007 Feb;13(2):202-205. doi: 10.1111/j.1469-0691.2006.01590.x.

32.

Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.

Panagiotakopoulou A, Daikos GL, Miriagou V, Loli A, Tzelepi E, Tzouvelekis LS.

Int J Antimicrob Agents. 2007 Mar;29(3):360-2. Epub 2007 Jan 12. No abstract available.

PMID:
17223016
33.

Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.

Loli A, Tzouvelekis LS, Tzelepi E, Carattoli A, Vatopoulos AC, Tassios PT, Miriagou V.

J Antimicrob Chemother. 2006 Sep;58(3):669-72. Epub 2006 Jul 26.

PMID:
16870645
34.

Antimicrobial susceptibility of Neisseria gonorrhoeae in Greece: data for the years 1994-2004.

Stathi M, Flemetakis A, Miriagou V, Avgerinou H, Kyriakis KP, Maniatis AN, Tzelepi E.

J Antimicrob Chemother. 2006 Apr;57(4):775-9. Epub 2006 Feb 21.

PMID:
16492719
35.

IS26-associated In4-type integrons forming multiresistance loci in enterobacterial plasmids.

Miriagou V, Carattoli A, Tzelepi E, Villa L, Tzouvelekis LS.

Antimicrob Agents Chemother. 2005 Aug;49(8):3541-3.

36.

Panresistance in VIM-1-producing Klebsiella pneumoniae.

Miriagou V, Tzelepi E, Daikos GL, Tassios PT, Tzouvelekis LS.

J Antimicrob Chemother. 2005 May;55(5):810-1. Epub 2005 Mar 16. No abstract available.

PMID:
15772141
37.

Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element.

Gangoue-Pieboji J, Miriagou V, Vourli S, Tzelepi E, Ngassam P, Tzouvelekis LS.

Antimicrob Agents Chemother. 2005 Jan;49(1):441-3.

38.

CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid.

Miriagou V, Tzouvelekis LS, Villa L, Lebessi E, Vatopoulos AC, Carattoli A, Tzelepi E.

Antimicrob Agents Chemother. 2004 Aug;48(8):3172-4.

39.

Novel GES/IBC extended-spectrum beta-lactamase variants with carbapenemase activity in clinical enterobacteria.

Vourli S, Giakkoupi P, Miriagou V, Tzelepi E, Vatopoulos AC, Tzouvelekis LS.

FEMS Microbiol Lett. 2004 May 15;234(2):209-13.

40.

Characterization of In111, a class 1 integron that carries the extended-spectrum beta-lactamase gene blaIBC-1.

Vourli S, Tzouvelekis LS, Tzelepi E, Lebessi E, Legakis NJ, Miriagou V.

FEMS Microbiol Lett. 2003 Aug 8;225(1):149-53.

41.

Characterization of Klebsiella pneumoniae clinical strains producing a rare extended-spectrum beta-lactamase (IBC-1).

Vourli S, Tzouvelekis LS, Tzelepi E, Kartali G, Kontopoulou C, Sofianou D, Tzouvelekis LS.

Int J Antimicrob Agents. 2003 May;21(5):495-7. No abstract available.

PMID:
12727088
42.

Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2.

Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM.

Antimicrob Agents Chemother. 2003 Apr;47(4):1297-300.

43.

Extended-spectrum beta-lactamase types in Klebsiella pneumoniae and Escherichia coli in two Greek hospitals.

Tzelepi E, Magana Ch, Platsouka E, Sofianou D, Paniara O, Legakis NJ, Vatopoulos AC, Tzouvelekis LS.

Int J Antimicrob Agents. 2003 Mar;21(3):285-8.

PMID:
12636993
44.

Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1.

Miriagou V, Tzelepi E, Gianneli D, Tzouvelekis LS.

Antimicrob Agents Chemother. 2003 Jan;47(1):395-7.

45.

CTX-m-3 beta-lactamase-producing Escherichia coli from Greece.

Mavroidi A, Tzelepi E, Miriagou V, Gianneli D, Legakis NJ, Tzouvelekis LS.

Microb Drug Resist. 2002 Spring;8(1):35-7.

PMID:
12002647
46.

Outbreak of infections caused by Enterobacter cloacae producing the integron-associated beta-lactamase IBC-1 in a neonatal intensive care unit of a Greek hospital.

Kartali G, Tzelepi E, Pournaras S, Kontopoulou C, Kontos F, Sofianou D, Maniatis AN, Tsakris A.

Antimicrob Agents Chemother. 2002 May;46(5):1577-80.

47.

An integron-associated beta-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1.

Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS.

J Antimicrob Chemother. 2001 Nov;48(5):627-30.

PMID:
11679551
48.

Multidrug-resistant strains of Neisseria gonorrhoeae in Greece.

Mavroidi A, Tzouvelekis LS, Kyriakis KP, Avgerinou H, Daniilidou M, Tzelepi E.

Antimicrob Agents Chemother. 2001 Sep;45(9):2651-4.

49.

Substitution of Thr for Ala-237 in TEM-17, TEM-12 and TEM-26: alterations in beta-lactam resistance conferred on Escherichia coli.

Giakkoupi P, Hujer AM, Miriagou V, Tzelepi E, Bonomo RA, Tzouvelekis LS.

FEMS Microbiol Lett. 2001 Jul 10;201(1):37-40.

50.

Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece.

Mavroidi A, Tsakris A, Tzelepi E, Pournaras S, Loukova V, Tzouvelekis LS.

J Antimicrob Chemother. 2000 Dec;46(6):1041-2. No abstract available.

PMID:
11102432

Supplemental Content

Loading ...
Support Center